Skip to main content

Table 1 Baseline characteristics of patients with NAFLD participated in our study before interventiona

From: Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial

Variables

Placebo group

Curcumin group

P value

Age (year)

10.9 ± 45.13

11.5 ± 46.19

0.473

Sex (male, n,(%))

14 (51.9%)

13 (48.1%)

0.407

Physical Activity (MET.h.d)

4.63 ± 32.03

3.65 ± 32.69

0.592

Smoking

  

0.167

 Yes (Smoker or Ex-smoker)

4 (17%)

1 (4%)

 

 No (Never smoked)

19 (83%)

26 (96%)

 

Weight (kilogram)

89.22 ± 13.05

85.02 ± 11.16

0.225

BMI (kg/m2)

32.38 ± 5.02

32.30 ± 4.55

0.956

Waist circumference (cm)

103.28 ± 8.83

102.19 ± 8.78

0.948

Total energy (kcal)

2323.01 ± 540.59

2355.41 ± 703.69

0.858

hs-CRP (ng/dL)

6705.05 ± 4797.9

5647.15 ± 3858.4

0.412

TNF-α (pg/mL)

18.63 ± 2.2

19.34 ± 5.4

0.610

NF-κB

2.13 ± 0.92

2.07 ± 1.03

0.842

Fibrosis grade (kPa)

6.52 ± 2.38

6.98 ± 2.42

0.132

Steatosis grade (db/m)

315.18 ± 35.69

298.35 ± 29.5

0.218

  1. aData are presented as mean ± SD except for gender, which is reported as number (%)
  2. NAFLD none-alcoholic Fatty Liver Disease, BMI body mass index, TNF tumor necrosis factor, NF-kB Nuclear factor kappa B, hs-CRP high sensitive C reactive protein